ISSN 2097-6046(网络)
ISSN 2096-7446(印刷)
CN 10-1655/R
主管:中国科学技术协会
主办:中华护理学会
重症护理研究

肺癌患者使用免疫检查点抑制剂后发生心脏毒性反应的护理

  • 胡汉 ,
  • 冯丹 ,
  • 何俊峰
展开
  • 310000 杭州市 浙江大学医学院附属第二医院护理部
胡汉:女,本科,副主任护师,E-mail:hh157581@zju.edu.cn

收稿日期: 2024-01-30

  网络出版日期: 2025-01-14

基金资助

浙江省教育厅一般科研项目(自然科学类Y202249636)

Nursing care of cardiotoxic adverse reactions caused by immune checkpoint inhibitors in patients with lung cancer

  • HU Han ,
  • FENG Dan ,
  • HE Junfeng
Expand

Received date: 2024-01-30

  Online published: 2025-01-14

摘要

总结3例肺癌患者使用免疫检查点抑制剂治疗后发生心脏毒性反应的护理体会。护理要点:及时评估并监测心脏毒性;安全给药以减轻心脏毒性反应;应用护理多学科协作模式完善专科护理;落实个性化出院随访促进患者早日康复。经及时干预、严密监测和综合管理,1例患者恢复良好,继续行免疫治疗,2例患者停止免疫治疗后行姑息治疗。随访半年,3例患者病情稳定。

本文引用格式

胡汉 , 冯丹 , 何俊峰 . 肺癌患者使用免疫检查点抑制剂后发生心脏毒性反应的护理[J]. 中华急危重症护理杂志, 2025 , 6(1) : 86 -88 . DOI: 10.3761/j.issn.2096-7446.2025.01.014

Abstract

To summarize the nursing experience of three lung cancer patients with cardiotoxic reactions after treatment with immune checkpoint inhibitors. Key points of care included timely assessment and monitoring of cardiotoxicity,safe drug administration to reduce cardiotoxic reactions,application of multidisciplinary nursing cooperation model to improve specialized nursing,implementing personalized discharge follow-up to promote early recovery of patients. After timely intervention,close monitoring and comprehensive management,one patient recovered well and continued immunotherapy,and two patients were treated with palliative therapy after stopping immunotherapy. The condition of three patients in this group was stable during six-month follow-up.

参考文献

[1] 周彩存, 王洁, 步宏, 等. 中国非小细胞肺癌免疫检查点抑制剂治疗专家共识(2019年版)[J]. 中国肺癌杂志, 2020, 23(2):65-76.
  Zhou CC, Wang J, Bu H, et al. Chinese experts consensus on immune checkpoint inhibitors for non-small cell lung cancer(2019 version)[J]. Chin J Lung Cancer, 2020, 23(2):65-76.
[2] 中华医学会呼吸病学分会肺癌学组. 免疫检查点抑制剂相关肺炎诊治专家共识[J]. 中华结核和呼吸杂志, 2019, 42(11):820-825.
  Lung Cancer Group of Respiratory Branch of Chinese Medical Association. Expert consensus on the diagnosis and treatment of pneumonia related to immune checkpoint inhibitors[J]. Chin J Tubere Respir Dis, 2019, 42(11):820-825.
[3] 孙涛. 2023版CSCO肿瘤心脏病学指南中化疗及免疫治疗心脏毒性的更新要点解读[J]. 实用肿瘤杂志, 2023, 38(5):434-439.
  Sun T. Interpretation of updates of 2023 CSCO guidelines for oncology cardiology:chemotherapy and immunotherapy section[J]. J Pract Oncol, 2023, 38(5):434-439.
[4] Kennedy LC, Wong KM, Kamat NV, et al. Untangling the multidisciplinary care web:streamlining care through an immune-related adverse events(IRAE) tumor board[J]. Target Oncol, 2020, 15(4):541-548.
[5] Swami U, Monga V, Bossler AD, et al. Durable clinical benefit in patients with advanced cutaneous melanoma after discontinuation of anti-PD-1 therapies due to immune-related adverse events[J]. J Oncol, 2019,2019:1856594.
[6] Salem JE, Manouchehri A, Bretagne M, et al. Cardiovascular toxicities associated with ibrutinib[J]. J Am Coll Cardiol, 2019, 74(13):1667-1678.
[7] 段磊, 胡宝祥, 司继刚. 糖皮质激素冲击治疗引发的不良反应及对策[J]. 儿科药学杂志, 2018, 24(1):51-53.
  Duan L, Hu BX, Si JG. Adverse reactions and strategies of glucocorticoid impulse therapy[J]. J Pediatr Pharm, 2018, 24(1):51-53.
[8] 江淑芬, 董畅, 刘莹, 等. 免疫检查点抑制剂相关心血管不良反应的机制、临床表现及管理[J]. 中华心血管病杂志, 2021, 49(4):410-413.
  Jiang SF, Dong C, Liu Y, et al. Mechanism,clinical manifestations and management of cardiovascular adverse reactions associated with immune checkpoint inhibitors[J]. Chin J Cardiol, 2021, 49(4):410-413.
[9] Ederhy S, Voisin AL, Champiat S. Myocarditis with immune check-point blockade[J]. N Engl J Med, 2017, 376(3):290-291.
文章导航

/